The Globe and Mail reports in its Thursday, May 7, edition that Desjardins Securities analyst Bryce Adams continues to rate Cameco "buy." The Globe's David Leeder writes in the Eye On Equities column that Mr. Adams gave his share target a $5 boost to $190. Analysts on average target the shares at $172.93. Mr. Adams says in a note: "Cameco reported a 1Q26 earnings beat and reaffirmed its guidance ranges; the stock opened higher but gave back early gains and was weaker alongside other uranium/ nuclear peers. We continue to view Cameco as best positioned in the uranium/nuclear market to capture macro tailwinds. We note that overall, the uranium market is still below replacement rates for long-term contracting volumes, and we see upside potential in Cameco shares as uranium demand outpaces supply while security of supply is a key factor for utilities." The Globe reported on June 18 that Mr. Adams had reaffirmed his "buy" recommendation for Cameco. The shares were then going for $94.51. The Globe reported on March 4 that Raymond James analyst Brian MacArthur had reaffirmed his "outperform" recommendation for Cameco, which was then going for $164.02.